According to a recent study, low-dose oral bisphosphonates administered to prevent or treat postmenopausal osteoporosis may be associated with a lower risk of skeletal metastasis in patients with early- or more advanced-stage breast cancer.
According to a recent study, low-dose oral bisphosphonates administered to prevent or treat postmenopausal osteoporosis may be associated with a lower risk of skeletal metastasis in patients with early- or more advanced-stage breast cancer.
The findings are based on analysis of health administrative data from a historical cohort of 21,664 women diagnosed with breast cancer in Quebec, Canada. Researchers from McGill University Health Centre stratified the cohort according to disease stage (0-II or III) at time of diagnosis. The primary outcome was time to development of bone metastasis. Exposure was considered bisphosphonate use prediagnosis, postdiagnosis, both, or neither, and a cumulative index of drug exposure.
In women with local disease at diagnosis, use of bisphosphonates only postdiagnosis or continuing on them after breast cancer diagnosis was associated with a decline in risk of bone metastasis from 45% to 28%. The reduction in risk associated with bisphosphonates was nearly 50% in women with regional disease who used the drugs postdiagnosis, regardless of whether they had used bisphosphonates prediagnosis.
Researchers also observed a statistically significant dose-response trend that related increased use with lower risk (slope = 0.94, 95% confidence interval = 0.90 to 0.99). Also, bisphosphonates were associated with a decreased risk of all-cause mortality similar to that for development of bone metastasis.
Editorial: Graduate medical education at crossroads
Investigators concluded that low-dose bisphosphonates used for the prevention or treatment of postmenopausal osteoporosis were tied to lower risk of skeletal metastasis in patients with early- and advanced-stage breast cancer.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More